Compare Eli Lilly And Co (LLY) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Altria Group Inc — how do they compare? Eli Lilly And Co trades at $1,139.39 (market cap $1.02T), while Altria Group Inc trades at $74.56 (market cap $124.67B). The key difference: Eli Lilly And Co is far larger — about 8.2× Altria Group Inc's market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| LLY | MO | |
|---|---|---|
Market Cap | $1.02T | $124.67B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $74.66 |
52-Week Low | $625.65 | $54.72 |
Enterprise Value | $1.06T | $145.75B |
Dividend Yield | 0.6% | 5.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Altria (MO) trades at $74.14, down slightly by 0.09% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 39.52% net income margin and consistent dividend payments, including a recent $1.06 dividend declared for July 2026. Revenue remains stable around $20.1B for 2025, though net income dipped to $6.95B from prior peaks. Analyst consensus is predominantly bullish with 16 buys and a $71.00 price target.
Outlook: MO offers a high-yield dividend appeal and defensive positioning amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Earnings beats in recent quarters provide support, though debt levels and competitive shifts in nicotine products warrant caution for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
